Drug intelligence / Profile preview

KIVU-495

Development stage: Preclinical
Lead developer: Kivu Bioscience
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

KIVU-495 is an antibody-drug conjugate (ADC) currently in preclinical development by Kivu Bioscience for the treatment of solid tumors. Designated as a development candidate, KIVU-495 is part of a pipeline that utilizes site-specific conjugation technologies to enhance the therapeutic index of ADCs by improving linker-payload stability and reducing off-target toxicity. The specific molecular target and the nature of the cytotoxic payload for KIVU-495 have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on KIVU-495.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KIVU-495.

Explore the full profile